---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-232481"
form_type: "8-K"
ticker: "MIRM"
cik: "0001759425"
company_name: "Mirum Pharmaceuticals, Inc."
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:47:37.610452+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Mirum appoints Eric Bjerkholt as CFO effective Sept 11, 2023

## Summary
- Eric Bjerkholt appointed CFO; previously CFO at Chinook Therapeutics and Aimmune Therapeutics.
- Base salary of $485,000 and annual bonus target of 40% of base salary.
- Granted option for 110,000 shares and RSU for 55,000 shares, both with four-year vesting.
- Severance: 9-month salary and 12-month equity acceleration outside CIC; 18-month salary +150% bonus + full acceleration within CIC.

## SEC filing metadata
- accession: 0001193125-23-232481
- form_type: 8-K
- ticker: MIRM
- cik: 0001759425
- company_name: Mirum Pharmaceuticals, Inc.
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1759425/000119312523232481/0001193125-23-232481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1759425/000119312523232481/d523866d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-232481
- JSON: https://secwatch.observer/filing/0001193125-23-232481.json
- Plain text: https://secwatch.observer/filing/0001193125-23-232481.txt

## Key facts
- Executive change
  Eric Bjerkholt was appointed as Chief Financial Officer at Mirum Pharmaceuticals, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: On September 11, 2023, Mirum Pharmaceuticals, Inc., (the “Company”) announced that the Board of Directors of the Company (the “Board”) appointed Eric Bjerkholt as the Chief Financial Officer of the Company, including as the “principal financial officer” of the Company within the meaning of Rule 16a-1(f) under the Securities Exchange Act of 1934, as amended, effective September 11, 2023 (the “Appointment Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1759425/000119312523232481/0001193125-23-232481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.